• Conference Proceeding

Evaluation of BRCA mutation (BRCAm) testing patterns, clinical characteristics and overall survival (OS) in breast cancer (BC) patients over a 20-year period

Citation

Stenehjem, D. D., Tyczynski, J., Unni, S. K., Bauer, H., Sainski, A., Deka, R., ... Biskupiak, J. E. (2015). Evaluation of BRCA mutation (BRCAm) testing patterns, clinical characteristics and overall survival (OS) in breast cancer (BC) patients over a 20-year period. In [33], p. e12518. .

Abstract

Background: BRCAm are implicated in 5% of BC. Since PARP inhibitors may be preferentially active in BRCAm carriers with BC, we evaluated historical BRCAm testing patterns, clinical characteristics, and OS in BC patients stratified by BRCAm status. Methods: Patients with BC treated at the University of Utah Huntsman Cancer Institute (HCI) from 1995-2014 were identified from an institutional tumor registry linked to the Enterprise Data Warehouse. Germline BRCAm status was ascertained by chart review. Univariate COX regression models evaluated relationships between BRCAm and OS from BC diagnosis. Results: Study had 5712 BC patients with BRCAm testing reported in 918 (16.1%). Testing increased from 4.7% in 1995-1999 to 26.2% in 2010-2014, p